SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
New Frontiers in STI Prevention
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
11 of
11
|
Introduction of Speakers Part 1
Missed Opportunities for Syphilis Diagnosis With Targeted Compared to Universal Screening (ABSTRACT
160)
Kimberly A. Stanford
University of Chicago Medical Center, Chicago, IL, USA
Higher Odds of Congenital Syphilis With 9- vs 7-Day Prenatal Treatment Intervals for Late Syphilis (ABSTRACT
161)
Kelly A. Johnson
University of California San Francisco, San Francisco, CA, USA
DoxyPEP Eligibility, Use, and Potential for STI Reduction in a Large HIV Cohort in Washington, DC (ABSTRACT
162)
Amanda D. Castel
The George Washington University, Washington, DC, USA
High Sustained Effectiveness of Doxycycline PEP for STI Prevention After Clinical Implementation (ABSTRACT
163)
Hyman Scott
San Francisco Department of Public Health, San Francisco, CA, USA
Questions and Answers Part 1
Introduction of Speakers Part 2
The Doxy-PEP Continuum Among Patients Receiving Care at a Sexual Health Clinic in San Francisco (ABSTRACT
164)
Michael P. Barry
San Francisco AIDS Foundation, San Francisco, CA, USA
Global Modelling Analysis: Impact of Improved HPV Vaccination on Noncervical Cancers in PLWHIV (ABSTRACT
165)
Namwa Wongkalasin
Imperial College London, London, UK
Impact of Urine TFV Testing on PrEP Adherence in South African Pregnant and Postpartum Women: An RCT (ABSTRACT
166)
Dvora L. Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
Questions and Answers Part 2
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
11 of
11
|
